论文部分内容阅读
随着世界范围内心血管类型疾病发病率的不断上升,心血管类复方制剂的新药也不断在上市、注册,但目前国内外对于这类药物并没有一个系统的质量研究及评价体系。药物相应的研发人员在该类药物的质量研究上存在着诸多问题,本文将就复方心血管类药物的开发现状、未来的展望进行评价,并对复方心血管类药物的特点及其相关质量研究所应考虑的一般问题及重点问题进行探讨,以供同行及相关研究人员参考。
With the rising incidence of cardiovascular diseases worldwide, new drugs for cardiovascular compounds have been listed and registered continuously. However, there is no systematic quality research and evaluation system for these drugs at home and abroad. Corresponding R & D personnel in the quality of the drug there are many problems on the study, this article will be on the development of compound cardiovascular drugs status quo, the future prospects of evaluation, and compound cardiovascular characteristics and related quality of the study The general issues to be considered and the key issues to be explored for reference by peers and relevant researchers.